GOTHENBURG, Sweden, March 27, 2025 — The Edinburgh Cancer Centre initiated the Precision Study last week, treating prostate cancer patients with just three radiation doses. The Raypilot System is being utilized to enhance motion control during treatment, aiming to reduce potential side effects. The study seeks to confirm that three sessions are as effective as five in terms of both cancer elimination and side effect severity.

The Pace-B study*, published in 2024, indicated that SBRT** involving five radiation sessions has the same effectiveness in cancer treatment as traditional methods requiring 20–40 sessions. The Precision Study is designed to further simplify the treatment process while lessening side effects and increasing patient comfort. The Raypilot System, which offers real-time monitoring of organ movement, is used for these treatments. The system facilitates urethra-sparing approaches and tighter radiation margins, improving targeting accuracy and minimizing the potential for side effects.

Striving for Enhanced Quality of Life

The study, led by Professor Duncan McLaren at the Edinburgh Cancer Centre in Scotland, involves 100 patients from various clinics in Europe and the US. His objective is to improve the comfort and post-treatment quality of life for prostate cancer patients.

“The Precision Study aims to ensure that treatment using three radiation doses does not result in more significant side effects than those seen in the Pace-B study. I am optimistic that we can demonstrate effective cancer treatment with fewer side effects,” states Professor McLaren.

A Joint Effort for Better Healthcare

The study originated from researchers at different clinics employing the Raypilot System.

“Our clients are committed to advancing and improving healthcare, with a constant focus on patient quality of life. Simultaneously, healthcare providers globally are working to shorten treatment durations and improve both quality and efficiency. This study has the potential to contribute to this progress, benefiting all involved – healthcare providers can reduce costs and improve care, while patients experience a better quality of life,” says Thomas Lindström, MD at Micropos Medical AB, the developer of the Raypilot System.

Initial findings from the Precision Study are anticipated within one to two years, followed by five years of patient follow-up before the final results are presented.

^*Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer, van As et al, N Engl J Med 2024;391:1413-1425 

^**SBRT (Stereotactic Body Radiation Therapy) consists of treatment administered in five or fewer sessions, over five or fewer consecutive days, delivering a significantly higher radiation dose per session compared to conventional treatment.

For more information, please contact:
Thomas Lindström
 +46 (0)31-760 80 05

This information was brought to you by Cision

The following files are available for download:

 

SOURCE Micropos Medical